摘要
【目的】 了解沙美特罗替卡松粉吸入剂(商品名:舒利迭)治疗中、重度儿童哮喘的临床治疗效果。 【方法】 收集了2009年1月-2010年3月本院哮喘门诊及住院的中、重度哮喘患儿46例,分别于吸入舒利迭治疗前及治疗3个月后,做肺通气功能及评价患儿临床控制情况。 【结果】 1)治疗3个月后肺通气功能明显改善:FEV1、PEF、FEF25、FEF50、FEF75、MMEF75/25治疗前分别为(1.31±0.59)、(3.05±1.33)、(2.39±1.17)、(1.30±0.69)、(0.52±0.28)、(1.08±0.60) L/S, 吸入舒利迭治疗3个月后分别为(1.90±0.59)、(4.45±1.35)、(3.80±1.17)、(2.34±0.80)、(0.98±0.39)、(2.10±0.82) L/S(治疗前、后比较t值依次为4.80、5.02、5.78、6.67、6.57、6.80;P均＜0.001);其中28例(60.9%)肺通气功能恢复正常,一项异常7例(15.2%),2项异常4例(8.7%),3项异常5例(10.9%),4项和5项异常各1例(2.2%),6项均异常0例;2)吸入舒利迭治疗3个月后87%(40例)的患儿达到临床控制,8.7%(4例)的患儿部分控制,4.3%(2例)未控制。 【结论】 吸入舒利迭可显著改善中、重度儿童哮喘临床症状及肺通气功能,是治疗年长儿童中、重度哮喘较为理想的药物,值得临床推广应用。
Abstract
【Objective】 To observe the efficacy of salmeterol/fluticasone(commodity name:Seretide) in the treatment of children with moderate and severe asthma. 【Method】 Evaluate the efficacy by lung ventilation function and clinical asthma control of the 46 moderate and severe asthmatic cases from our outpatient department and the hospital during January 2009 and March 2010 treated by Seretide. 【Results】 1)Significant improvement on the lung ventilation function was founded after 3 months treatment by Seretide. Before the treatment:FEV1、PEF,FEF25 ,FEF50,FEF75,MMEF75/25were (1.31±0.59),(3.05±1.33),(2.39±1.17),(1.30±0.69),(0.52±0.28),(1.08±0.60) L/S;after 3 months treatment, FEV1,PEF,FEF25,FEF50,FEF75,MMEF75/25 were (1.90±0.59),(4.45±1.35),(3.80±1.17),(2.34±0.80),(0.98±0.39),(2.10±0.82) L/S(t=4.80,5.02,5.78,6.67,6.57,6.80;all P<0.001);of which 28 patients (60.9%) lung ventilation function returns to normal, a abnormal 7 cases (15.2%), two anomalies in 4 (8.7%) ,3 of abnormal in 5 patients (10.9%), four and five abnormal each 1 cases (2.2%), and six indexes abnormal 0); 2)87%(40 cases )of children were clinical controlled , 8.7% (4 cases)of children were partially controlled, 4.3% (2 cases)were not controlled. 【Conclusions】 Seretide can significantly improve moderate and severe children asthma clinical symptoms, lung ventilation function. So, it is an ideal treatment of the older children, moderate and severe asthma, to be worth of clinical application.
关键词
沙美特罗替卡松粉吸入剂 /
治疗 /
儿童 /
哮喘
Key words
salmeterol/fluticasone /
treatment /
children /
asthma
马彩玲,段波,田玉珍.
沙美特罗替卡松粉吸入剂治疗中、重度儿童哮喘的临床疗效观察[J]. 中国儿童保健杂志. 2011, 19(11): 1033-1035
MA Cai-ling,DUAN Bo,TIAN Yu-zhen.
Analysis of therapeutic effect of salmeterol/fluticasone on moderate and severe children asthma treated by inhalation[J]. Chinese Journal of Child Health Care. 2011, 19(11): 1033-1035
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
参考文献
[1] 全国儿童哮喘防治协作组.中国城区儿童哮喘患病率调查[J].中华儿科杂志,2003,41(2):123-127.
[2] 中华医学会儿科分会呼吸学组,《中华儿科杂志》编辑委员会.儿童支气管哮喘诊断与防治指南[J].中华儿科杂志,2008,46(10):745-753.
[3] 李明华,殷凯生,蔡映云.哮喘病学[M].2版 北京:人民卫生出版社,2005:33-38.
[4] Maspero J,Guerra F,Cuevas F,et al.Efficacy and tolerabilityof salmeterol/fluticasone propionate versus montelukast in childhood asthma:A prospective,randomized,double-blind, double-dummy,parallel-group study[J].Clinical Therapeutics,2008,30(8):1492-1504.
[5] De Blic J,Ogorodova L,Klink R,et al.Salmeterol/ fluticasone propionate vs.double dose fluticasone propionate on lung function and asthma control in children[J].Pediatr Allergy Immunol,2009,20(8):763-771.
[6] 毛春发.舒利迭治疗儿童中、重度哮喘50例疗效分析[J].浙江中医学大学学报,2009 ,33(4):553-554.
[7] 朱毅,陆丽华.舒利迭与辅舒酮治疗儿童中、重度支气管哮喘的治疗比较[J].吉林医学,2009,30(9):845-846.
[8] 艾涛,罗荣华,王次林.沙美特罗/丙酸氟替卡松对哮喘儿童肺部功能改变及临床意义[J].儿童药学杂志,2004,10(4):21-22.
PDF(451 KB)
